Device Trial Radar · NCT00131365
Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids
Last checked: Nov 20, 2026Latest source record: Jun 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Jan 2006
Primary completion
Jan 2009
Study completion Feb 2009
Sponsor
- Lead sponsor
- InSightecNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 18, 2005
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to develop additional long term data to evaluate the safety and effectiveness of this treatment. Indications for use for this system is: 'The ExAblate is intended to ablate uterine fibroid tissue in pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure. Patients must have a uterine size of less than 24 weeks and not seeking treatment for reasons of improving fertility.'
Conditions
- Leiomyoma
Interventions
ExAblate 2000Device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and Type of Adverse EventsTime frame: 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cornell Vascular
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.